STC-1010

STC-1010 is an off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines (the company calls it an in vivo DC-engager) from Brenus Pharma. Made from selected allogeneic human cancer cell lines (Stimulated-Ghost-Cells); the company describes it as an in vivo DC-engager designed to make immunologically 'cold' tumours visible to immune cells. It is given with oral low-dose cyclophosphamide, with or without GM-CSF, alongside first-line chemotherapy. Its furthest stage is phase 1, for unresectable locally advanced or metastatic pMMR/MSS colorectal cancer. ClinicalTrials.gov registers it in one study linked below. Phase I/IIa BreAK CRC-001 (NCT06934538, registry PHASE1/PHASE2, recruiting); phase Ia dose-escalation data at ESMO 2026 (press release 23 Oct 2026). FDA accepted the IND in May 2026. Whether it works in people has not been established unless a trial below reports it.